Introduction
Despite the wealth of research on screening for and prevention of pre-eclampsia (PE) published in the last three decades, this condition remains one of the main causes of maternal and perinatal morbidity and mortality, both in low-and high-income countries. It affects 2-8% of all pregnancies, being responsible for one out of five maternal deaths and 15% of all preterm deliveries 1 . An ideal screening test requires identification of women at high-risk of developing severe and early-onset forms of the disease, a high detection rate (DR) with an acceptable false-positive rate (FPR) and the availability of an effective preventive measure 2 . The positive predictive value of any test relies on the prevalence of the disease and, as preterm PE is relatively uncommon, the positive predictive value of PE screening tests is naturally low 1, 2 , thus DR and FPR are better indicators of accuracy. The definition of an acceptable FPR depends on the benefits and risks of the subsequent intervention 2 . Such screening could prove cost-effective since it would reduce the healthcare cost related to PE-associated morbidity and prevent unnecessary interventions in low-risk patients.
Most current screening methods adopted by national guidelines are based on a combination of maternal characteristics with medical, obstetric and family histories 3, 4 . Although these methods are simple and easy to perform, either the DR is poor or the screen-positive rate is very high 5 .
An alternative approach involves using a combination of maternal characteristics and history with biophysical and biochemical markers to estimate the individual post-test probability of developing PE. This approach seems to have higher DR for preterm PE and lower FPR [5] [6] [7] . Aspirin was first associated with lower risk of PE in high-risk women in 1978 8 . Since then, this association has been investigated in more than 30 randomized trials, with highly heterogeneous methods in terms of population and dose and time of initiation of aspirin, and consequent controversial results 9 . An individual patient data meta-analysis, known as the PARIS (Perinatal Antiplatelet Review of International Studies) study, showed a very modest effect of aspirin in the reduction of PE 10 . Most of the included studies initiated aspirin treatment after 16 weeks' gestation, used a dose of less than 100 mg and did not prescribe aspirin intake at bedtime, which are three factors possibly associated with treatment failure. A second meta-analysis using the same dataset also failed to demonstrate differences in starting the prophylaxis before or after 16 weeks' gestation 11 . Conversely, other recent meta-analyses suggested that the effect of aspirin on the prevention of PE is dose-dependent and that initiation of this treatment before 16 weeks' gestation halves the risk of PE, particularly reducing the severe and preterm forms of the disease [12] [13] [14] [15] . A possible explanation for the apparently controversial results is that the most common dose in the PARIS study was 75 mg or less and the secondary analysis did not specifically evaluate aspirin at doses higher than 100 mg initiated before 16 weeks' gestation.
The observation of Roberge et al. 13 of the beneficial effect of aspirin on PE, was criticized due to possible low power and publication bias 16 and absence of a major trial to confirm such findings, whilst most large trials using 60 mg of aspirin daily failed to observe a benefit of such intervention 15, 17 . These criticisms were then addressed by two major studies. First, Park et al. performed a retrospective cohort analysis of 7783 pregnancies showing that a combination of first-trimester PE screening with a daily dose of 150 mg of aspirin in high-risk women reduced the risk of preterm PE by 55% in that population 18 . More recently, the ASPRE trial 19 , involving screening of 26 941 women and randomization of 1776 participants, showed a significant 62% reduction of preterm PE when aspirin was given at a daily dose of 150 mg and initiated before 14 weeks' gestation. The effect of aspirin on term PE was minimal, and there was no significant effect on other maternal or neonatal adverse outcomes, in particular severe maternal morbidity, perinatal mortality and neonatal morbidity, although the study was underpowered for such outcomes. The trial did, however, identify a trend for reduction in stillbirth, neonatal death, birth weight below the 10 th percentile and respiratory distress syndrome requiring surfactant and ventilation 19 . In this Editorial, we discuss important aspects relating to clinical implementation of early screening for and prevention of PE.
Impact of PE on maternal and perinatal health
Over 76 000 maternal deaths and more than 500 000 perinatal deaths are caused by PE every year 20 . In the cases that require preterm delivery, the burden of prematurity is considerable.
Although the disease resolves with delivery, the incidence of PE can also impact on future maternal cardiovascular health. It is unknown whether PE predisposes women to cardiovascular complications or it represents an early manifestation triggered by pregnancy. A recent systematic review and meta-analysis of observational studies, including more than 6 million women and more than 258 000 cases of PE, showed that women with a history of PE have a four-fold increased risk of future heart failure and a two-fold increased risk of coronary heart disease, stroke and death from cardiovascular causes, when compared with women that did not develop PE during pregnancy 21 . The association of PE with increased cardiovascular risk later in life is also related to the severity and gestational age at onset of the condition 22 . These findings by themselves constitute a good justification to identify high-risk women promptly and implement preventive measures, but it is unknown whether aspirin intake during pregnancy can prevent such long-term cardiovascular outcomes.
Inversion of the pyramid of prenatal care
For the last 80 years, routine prenatal care involved a first visit at 16 weeks' gestation and a concentration of visits in the second and, mainly, in the third trimesters of pregnancy. Since the early 1990s, however, there has been a shift towards attempting to predict pregnancy complications in the first trimester 23 . Early identification of high-risk women allows appropriate counseling regarding changes in lifestyle (such as healthy diet, exercising and weight-monitoring recommendations) and early initiation of other preventive measures 23 . For some complications, such as early-onset PE leading to preterm delivery, recent evidence shows that pharmacological prophylaxis is most effective when started before 16 weeks' gestation 12, 19 . An integrated antenatal visit at 11 + 0 to 13+ 6 weeks' gestation provides a framework for population-based screening and preventive interventions which can be completed at the same time as the well-established process of first-trimester screening for chromosomal abnormalities.
Screening for PE

Current guidelines
The traditional approach to screening for PE is based on assessment of maternal characteristics (such as ethnicity, weight, height) and medical and obstetric history. Two common methods used to identify women at high-risk for developing PE are defined by the American College of Obstetricians and Gynecologists (ACOG) and the National Institute for Health and Care Excellence (NICE) guidelines 3, 4, 24 . According to the ACOG recommendations, women are considered at high-risk for developing PE if they have any risk factor for PE 3 (Table 1 ). This method of screening, therefore, attributes the same predictive value to all risk factors and results in a very high screen-positive rate, identifying almost two-thirds of the population as high-risk 5 (Table 2) . However, according to the ACOG recommendations, the use of aspirin should be reserved for women with history of PE requiring delivery at < 34 weeks' gestation or PE in two or more previous pregnancies 25 . This very specific group comprises only 0.2% of all pregnancies and includes only 5% of the cases of preterm PE 5 ( Table 2 ). The NICE guidelines define women as being at high-risk of developing PE if they have one high-risk factor or any two moderate-risk factors 4 (Table 1) . Using this approach, 34 .
only about 40% of the patients that will develop preterm PE are identified as high-risk 5 ( Table 2 ). Whilst maternal factors provide important information for PE risk assessment, they do not perform well when used alone, primarily due to poor specificity. Manipulating baseline risks by including factors that either reduce or increase the risk of PE through addition of other predictive markers would logically enhance the predictive accuracy and reduce the number of false-positive results 26 .
Combined screening
Many studies published in the last few decades attempted to create predictive models for PE based on individual risk calculation derived from multiple logistic regression equations that combined maternal factors with different combinations of markers 7, [26] [27] [28] [29] [30] [31] [32] [33] [34] . The main criticism of these models is that they often lack internal and external validation, leading to a possibly higher performance in the development of the model than in its subsequent prospective applications (overfitting) 35, 36 . The most frequently used predictive algorithm for PE is the one developed by The Fetal Medicine Foundation (FMF) 7, 26, 31 . The authors reported that mean arterial pressure (MAP) and mean uterine artery pulsatility index (UtA-PI) between 11 + 0 and 13 + 6 weeks' gestation are higher in women that will later develop PE, and are particularly raised in those who develop early-onset PE, compared with unaffected pregnancies 7 . Similarly, biochemical markers that reflect placental function, such as placental growth factor (PlGF) and pregnancyassociated plasma protein-A (PAPP-A), are significantly reduced in the first trimester in patients that will later present with preterm PE. Therefore, the addition of these markers to maternal factors increases the DR, being able to detect more than 90% of the cases of PE that will require delivery before 32 weeks and about 75% of all cases of preterm PE 7, 34 (Table 2) . From this perspective, the FMF algorithm is superior to screening by maternal factors alone, with a higher area under the receiver-operating characteristics (ROC) curve (AUC) 5 . This predictive algorithm was externally validated in prospective studies involving different populations, and showed similar DR at the same FPR when compared with the original development of the algorithm 6, 37 , although other studies have shown a significant AUC but lower DR 38 . The prevalence (a-priori risk) of PE may vary depending on the characteristics of the population tested, which is the most likely reason for variation in validation studies.
Different combination of markers
Another challenge in implementing a patient-specific risk calculation is that biochemical tests may be difficult to perform in low-income settings or in countries in which first-trimester screening for chromosomal abnormalities is not well-established. In this sense, it is important to highlight that other combinations of markers with maternal characteristics and history also perform better than maternal factors alone 6, 7 . The addition of only MAP and UtA-PI to maternal factors allows detection of 70% of cases of preterm PE with a minimal increase in cost 6, 7 .
Quality control
Similar to the measurement of nuchal translucency and other markers in screening for fetal chromosomal abnormalities, systematic error in biomarker measurement can potentially under-or overestimate the risk of PE and impact significantly on the performance of first-trimester combined screening for PE. It is, therefore, crucial to ensure that MAP and UtA-PI are measured according to previously standardized techniques [39] [40] [41] [42] . Biophysical and biochemical parameters should be expressed as multiples of the median (MoM) after adjustment for maternal characteristics, and monitoring the median values in relation to the expected value of one MoM is necessary. While UtA-PI tends to be measured consistently by trained operators 43 , with moderate intra-and interobserver reproducibility 44, 45 , median MAP values may vary in different populations. Median biochemical marker values are also subject to slight variations as different providers and reagent batches can produce slightly different results. In case of systematic error, retraining operators or implementing corrective factors (a number by which each result should be multiplied for adjustment) may be needed.
Cut-off
In the ASPRE trial 19 , a risk cut-off of 1 : 100 led to a screen-positive rate of 11%. This threshold identified 76% of the women with PE requiring delivery before 37 weeks at a FPR of 9.2% 34 . Different health systems and public health policy makers, however, may choose other cut-off values in view of resource limitations and variations in the prevalence of PE in their population. The prevalence of PE in each setting and the screen-positive rates for different cut-offs should be determined prior to the clinical implementation of a predictive algorithm.
Although in some cases the chosen cut-off may be similar to the prevalence of the condition in the general population 46 , a comparison between the prevalence of the condition among screen-positive and screen-negative women (and the resulting positive likelihood ratio) can elucidate the discriminant power of the test.
Prevention of PE
There is now convincing evidence that aspirin (150 mg daily 19 , at bedtime 47 ) reduces the risk of preterm PE by more than 60% and the risk of early-onset PE by more than 80% when given to high-risk women from before 16 weeks' gestation 12, 19 (Table 3) . The same beneficial effect does not seem to be present in women with chronic hypertension 48 . Aspirin is effective, readily available, cheap and safe to use during pregnancy, justifying clinical implementation of screening in the first trimester. There is a clear dose-dependent effect, with high rates of resistance to aspirin's effect on platelet function with daily doses of less than 100 mg 13, 49 .
Mechanism of action
The precise mechanism of action by which aspirin reduces the risk of preterm PE is unknown. Theories include improvement of placentation via anti-inflammatory action, reduction of placental apoptosis and decrease in endothelial dysfunction markers 50 .
A recent in-vitro model showed that aspirin modulates and restores PE serum-induced alterations in cytokine levels, increases PlGF, improves placental cell differentiation and reduces apoptosis 50 . There are conflicting data as to whether aspirin improves deep placentation, with inconsistent results on the improvement of UtA-PI in different studies 51, 52 .
Cost-effectiveness
Screening for PE seems to be cost-effective when compared with no screening. The higher the prevalence of the disease, the more cost-effective the prediction 53 , and PE screening in the first trimester does not appear to increase maternal anxiety 54 . A cost-benefit analysis carried out in the USA showed that prescribing aspirin to a selected high-risk population is more cost-beneficial when compared with universal prophylaxis and no intervention policies 55 . This approach would likely reduce PE-related morbidity and mortality healthcare costs.
However, since possible beneficial effects of screening and prevention of PE on maternal and perinatal morbidity and mortality are yet to be proven, conclusions of cost-effectiveness studies may be somewhat misleading. Larger trials focusing on specific maternal and perinatal outcomes are needed.
Safety
The use of low-dose aspirin during pregnancy is considered to be safe. Previously published randomized trials and systematic reviews have reported no or few side-effects of aspirin administration 10, 19, 56 . A previous study showed no increase in morbidity at 2 years of age in children whose mothers received a daily dose of 60 mg of aspirin during pregnancy 57 . In the recently published ASPRE trial, the occurrence of side effects was no higher in the aspirin group than in the placebo group 19 . Although this is reassuring, caution is recommended, as long-term follow-up data for both mothers and infants are limited.
Universal prophylaxis
In view of the apparently reassuring safety of aspirin use during pregnancy, the idea of universal prophylaxis has been debated in the literature 58 . Nevertheless, it is important to highlight that aspirin may not have the same treatment effect in low-risk women as it does in a specific high-risk target population 59 . The limited long-term safety data available demand caution, since universal prophylaxis would reflect in the prescription of aspirin to millions of pregnant women and could lead to an increase in side effects. This policy would have poor positive predictive value and, consequently, compliance to treatment among all pregnant women would be lower in the absence or unawareness of high-risk indicators for PE, than adherence among high-risk women. Even worse, high-risk women might not even become aware of their risk and be falsely reassured due to absence of an effective screening test.
Limitations and future perspectives
Although first-trimester screening for preterm PE can identify a high proportion of women that will be affected by this condition, no predictive marker is good enough when used alone. Identifying potentially superior predictive markers is the focus of ongoing research. Additionally, the prediction of term PE is still poor, raising the hypothesis that the mechanism of disease is different in these cases 60 . Early-onset and preterm PE are associated with a very high risk of maternal and perinatal morbidity and mortality, but term PE and its consequences have a significant impact on public health since this condition is more common. Aspirin significantly reduces the risk of preterm PE but has little or no effect on term PE. Better methods of prediction and prevention of term PE are needed. Furthermore, although it is logical to assume that a reduction of the prevalence of preterm PE would lead to subsequent decrease in maternal and perinatal adverse outcomes, adequately powered trials specifically investigating the occurrence of such adverse events are needed.
It would also be interesting to identify the maternal characteristics associated with poor response to aspirin in women that develop preterm PE even when adherent to treatment.
Another question that should be addressed is whether aspirin use during pregnancy prevents long-term cardiovascular complications or whether the cardiovascular profile of high-risk women cannot actually be changed by prophylaxis during the gestational period.
Conclusions
Universal prophylaxis of preterm PE with aspirin should not be recommended in view of the low prevalence of the disease, possible low adherence to treatment and lack of long-term safety data.
Screening for PE by a combination of maternal characteristics and history with predictive biophysical and biochemical markers using the FMF algorithm is superior to screening by maternal factors alone. The calculation of patient-specific risk is feasible in the first trimester and allows detection of a high proportion of PE cases with acceptable FPR. Clinical implementation of the algorithm demands a prior analysis of the local population and constant quality control, while new studies investigating cost-effectiveness and the impact on maternal and perinatal adverse outcomes are needed. However, the significant risk reduction with aspirin treatment and the burden of preterm PE for mothers and babies justify the implementation in clinical practice of first-trimester screening and prescription of 150 mg of aspirin daily, at bedtime, for high-risk patients.
